Benedetta Peruzzi
YOU?
Author Swipe
View article: Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance
Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance Open
Background. The aim of intensive induction treatment in acute myeloid leukemia (AML) is the achievement of complete remission (CR). After the establishment of “3+7” regimen as the standard induction, several efforts were pursued for improv…
View article: Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction Open
Introduction: Despite the approval of novel agents that have significantly improved long-term survival rates for multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), most patients eventually relapse. The failur…
View article: Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML Open
CEBPA-mutated acute myeloid leukemia (AML) is recognized as a distinct entity in WHO and ICC classification. Several additional gene mutations are enriched in this subset compared to CEBPA-wild type AML, including recurrent myeloid mutatio…
View article: Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents Open
View article: A Rare Onset of T-Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
A Rare Onset of T-Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations Open
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by bone marrow expansion and the proliferation of one or more myeloid cell lineages, predominantly driven by the expression of the constitutively active fusion p…
View article: HPLC and flow cytometry combined approach for HbF analysis in fetomaternal haemorrhage evaluation
HPLC and flow cytometry combined approach for HbF analysis in fetomaternal haemorrhage evaluation Open
View article: Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms Open
View article: A Rare Onset of T Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations
A Rare Onset of T Lymphoid Blast Crisis in Chronic Myeloid Leukemia with Two Distinct Blast Populations Open
In chronic myeloid leukemia (CML), a clonal proliferative disorder of granulocytic lineage, the 90%‐95% of cases are characterized by t(9;22) (q34.1;q11.2) translocation, leading to the Philadelphia chromosome (1). Rarely, CML patients dir…
View article: The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in <i>CEBPA</i>-Mutated Acute Myeloid Leukemia
The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in <i>CEBPA</i>-Mutated Acute Myeloid Leukemia Open
Background: CEBPA-mutated acute myeloid leukemia (AML) is a separate entity in the updated WHO and ICC classifications. Previously identified by double mutations, the clinical profile and favorable outcome were correlated with in-frame mut…
View article: AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications
AML-251 APL-Like Subset Within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating With Early-Onset Vascular Complications Open
View article: P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA Open
Background: Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia (AML). In the early phases of treatment, MRD refines risk stratification and is used for the allocation to allogeneic transplant. Ho…
View article: Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia Open
Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia (AML). In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant…
View article: P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Open
Background: Flow-cytometry is considered crucial for monitoring multiple myeloma (MM) patients, in particularly for evaluation of minimal residual disease (MRD) [1]. Routinely MRD on bone marrow aspirate is the optimal method for assessing…
View article: Corrigendum to < Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience><Translational Oncology, 26C (2022) 101552]>
Corrigendum to < Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience> Open
View article: Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience
Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience Open
The identification of mature T cell neoplasms by flow cytometry is often challenging, due to overlapping features with reactive T cells and limitations of currently available T cell clonality assays. The description of an antibody specific…
View article: Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization Open
View article: Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis Open
Relapsing-remitting multiple sclerosis (RRMS) is a demyelinating disease in which pathogenesis T cells have a major role. Despite the unknown etiology, several risk factors have been described, including a strong association with human leu…
View article: Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis Open
Prognostic modeling in myelofibrosis (MF) has classically pursued the integration of informative clinical and hematological parameters to separate patients' categories with different outcomes. Modern stratification includes also genetic da…
View article: Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization
Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization Open
Background Waning immunity and the surge of SARS-CoV-2 variants are responsible for breakthrough infections, i.e. infections in fully vaccinated individuals. Although the majority of vaccinated infected subjects reports mild or no symptoms…
View article: Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience Open
Relapsed/refractory (R/R) acute myeloid leukemia (AML) is a largely unmet medical need, owing to the lack of standardized, effective treatment approaches, resulting in an overall dismal outcome. The only curative option for R/R AML patient…
View article: EBV-Associated Post-Transplant Lymphoproliferative Disease (PTLD) in Allogeneic Transplantation
EBV-Associated Post-Transplant Lymphoproliferative Disease (PTLD) in Allogeneic Transplantation Open
Post-Transplant Lymphoproliferative Disease (PTLD) following both Solid Organ Transplantation (SOT) and Hematopoietic Stem Cell Transplantation (HSCT) is a rare life-threatening complication. The majority of PLTDs are associated to Epstein…
View article: Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category
Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category Open
Acute myeloid leukemia (AML) “with myelodysplasia-related changes (MRC)” is considered a separate entity by the World Health Organization (WHO) classification of myeloid neoplasms. While anamnestic and cytogenetic criteria provide objectiv…
View article: Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS‐CoV‐2 infection
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS‐CoV‐2 infection Open
Summary SARS‐CoV‐2 is responsible for a new infectious disease (COVID‐19) in which individuals can either remain asymptomatic or progress from mild to severe clinical conditions including acute respiratory distress syndrome and multiple or…
View article: Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study Open
View article: Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent Open
BACKGROUNDCoronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune respons…
View article: The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies Open
Natalizumab (NTZ) and autologous hematopoietic stem cell transplantation (AHSCT) are two successful treatments for relapsing-remitting multiple sclerosis (RRMS), an autoimmune T-cell-driven disorder affecting the central nervous system tha…
View article: Dataset: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies
Dataset: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies Open
This dataset, containing TCRbeta-chain data, is the basis for the following publication in Frontiers in Immunology: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies. The…
View article: Dataset: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies
Dataset: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies Open
This dataset, containing TCRbeta-chain data, is the basis for the following publication in Frontiers in Immunology: The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies. The…
View article: PF229 CLUSTER ANALYSIS IDENTIFIES A SPECIFIC IMMUNOPHENOTYPIC PROFILE ASSOCIATED WITH HIGH RISK OF PRIMARY INDUCTION FAILURE AND SHORTER OVERALL AND DISEASE‐FREE SURVIVAL IN NPM1‐MUTATED AML
PF229 CLUSTER ANALYSIS IDENTIFIES A SPECIFIC IMMUNOPHENOTYPIC PROFILE ASSOCIATED WITH HIGH RISK OF PRIMARY INDUCTION FAILURE AND SHORTER OVERALL AND DISEASE‐FREE SURVIVAL IN NPM1‐MUTATED AML Open
Background: NPM1‐mutated acute myeloid leukemia is a clinically heterogeneous disease entity encompassing different risk categories; despite growing knowledge on the impact of concurrent mutations, part of this biological and clinical hete…
View article: The experience of Careggi Hospital (Florence) about Not Received Samples (NRS): a pilot study of Risk Management in Clinical Laboratory
The experience of Careggi Hospital (Florence) about Not Received Samples (NRS): a pilot study of Risk Management in Clinical Laboratory Open
Not available. Letter to Editor.